ID   NCC-LMS1-C1
AC   CVCL_LK56
SY   NCCLMS1C1
DR   DepMap; ACH-002785
DR   Wikidata; Q54907616
RX   PubMed=28981730;
RX   PubMed=29845452;
WW   Provider; BizCom; -; https://en.cellline.jp/product/ncc-lms1-c1/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo, Tadashi).
CC   Doubling time: 88 hours (PubMed=29845452).
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Derived from site: Metastatic; Bone, rib; UBERON=UBERON_0002228.
ST   Source(s): PubMed=28981730
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 9
ST   D16S539: 9
ST   D21S11: 30
ST   D5S818: 11
ST   D7S820: 8,11
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C7154; Bone leiomyosarcoma
DI   ORDO; Orphanet_64720; Leiomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VM07 ! NCC-LMS1-X3-C1
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 10-04-25; Version: 10
//
RX   PubMed=28981730; DOI=10.1093/jjco/hyx096;
RA   Sakumoto M., Takahashi M., Oyama R., Takai Y., Kito F., Shiozawa K.,
RA   Qiao Z.-W., Yoshida A., Endo M., Kawai A., Kondo T.;
RT   "Establishment and proteomic characterization of NCC-LMS1-C1, a novel
RT   cell line of primary leiomyosarcoma of the bone.";
RL   Jpn. J. Clin. Oncol. 47:954-961(2017).
//
RX   PubMed=29845452; DOI=10.1007/s11626-018-0258-2;
RA   Oyama R., Takahashi M., Kito F., Sakumoto M., Shiozawa K., Qiao Z.-W.,
RA   Yoshida A., Endo M., Kawai A., Kondo T.;
RT   "Establishment and characterization of patient-derived xenograft and
RT   its cell line of primary leiomyosarcoma of bone.";
RL   In Vitro Cell. Dev. Biol. Anim. 54:458-467(2018).
//